This study aimed to investigate the efficacy and tolerability of Lacosamide (LCM) in a pediatric population with epilepsy using LCM serum concentration and its correlation to the age of the participants and the dosage of the drug. Demographic and clinical data were collected from the medical records of children with epilepsy treated with LCM at Shamir Medical Center between February 2019 to September 2021, in whom medication blood levels were measured. Trough serum LCM concentration was measured in the biochemical laboratory using High-Performance Liquid Chromatography (HPLC) and correlated with the administered weight-based medication dosing and clinical report. Forty-two children aged 10.43 ± 5.13 years (range: 1-18) were included in the study. The average daily dose of LCM was 306.62 ± 133.20 mg (range: 100-600). The average number of seizures per day was 3.53 ± 7.25 compared to 0.87 ± 1.40 before and after LCM treatment, respectively. The mean LCM serum concentration was 6.74 ± 3.27 mg/L. No statistically significant association was found between LCM serum levels and the clinical response ( = 0.58), as well as the correlation between LCM dosage and the change in seizure rate ( = 0.30). Our study did not find a correlation between LCM serum concentration and LCM dosage and the gender of the participants: males (n = 17) females (n = 23) ( = 0.31 and = 0.94, respectively). A positive trend was found between age and LCM serum concentrations (r = 0.26, = 0.09). Based on the data that has been obtained from our study, it appears that therapeutic drug monitoring for LCM may not be necessary. Nonetheless, further research in this area is needed in the light of the relatively small sample size of the study.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10359424 | PMC |
| http://dx.doi.org/10.3389/fphar.2023.1164902 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Chronic exposure to liquid crystal monomer EBCN at environmentally relevant concentrations induces testicular dysfunction via the gut-testis axis.
J Hazard Mater
December 2024
Reproductive Medicine Center, Henan Provincial People's Hospital, Zhengzhou, China; Reproductive Medicine Center, Zhengzhou University People's Hospital, Zhengzhou, China; Henan Joint International Research Laboratory of Reproductive Bioengineering, Zhengzhou, China. Electronic address:
4-Cyano-4'-ethoxybiphenyl (EBCN) is a representative cyano liquid crystal monomer (LCM). While prior studies have documented the widespread occurrence of LCMs in diverse environmental and biological samples, research on their reproductive effects in vivo remains limited. This study employed 35-day and 70-day exposure models in mice to assess the short-term and long-term effects of environmentally relevant concentrations of EBCN on testicular health.
View Article and Find Full Text PDFNew Plant Extracts Exert Complementary Anti-Hair Loss Properties in Human In Vitro and Ex Vivo Models.
J Cosmet Dermatol
December 2024
University of Geneva, Geneva, Switzerland.
Background: Hair loss is linked to dysfunction of the growth (anagen), regression (catagen) and rest (telogen) phases of the hair follicle (HF) cycle.
Aims: To evaluate the effects of a Silybum marianum extract (SME), manganese PCA (MnPCA), and a Lespedeza capitata extract (LCE) on markers of hair growth and anchorage in human follicle dermal papilla cells (HFDPCs), and to investigate the ability of a topical serum containing these active ingredients to improve HF growth in an ex vivo human scalp skin model.
Methods: In HFDPCs, we assessed receptor tyrosine kinase phosphorylation and Wnt/β-catenin pathway activation; quantified versican, vascular endothelial growth factor (VEGF) and Dickkopf-1 (DDK1) secretion; and evaluated 5α-reductase (5αR) activity.
Non-inferiority study of purified Vero rabies vaccine - serum free in three-dose and two-dose pre-exposure prophylaxis regimens in comparison with licensed rabies vaccines.
Clin Infect Dis
November 2024
Clinical Development, Sanofi Vaccines, Singapore.
Background: A next-generation, serum-free, highly purified Vero cell rabies vaccine, PVRV-NG2, is in development.
Methods: This multicenter, observer-blind, phase 3 study evaluated the immunogenicity and safety of PVRV-NG2, compared with two licensed rabies vaccines (purified Vero cell rabies vaccine [PVRV] and human diploid cell vaccine [HDCV]), as a pre-exposure prophylaxis (PrEP) regimen. Participants were randomized 3:1:1 to PVRV-NG2, PVRV, or HDCV, as a three-dose (Cohort 1; children and adults; day [D] 0, D7, and D28) or two-dose (Cohort 2; adults; D0 and D7) PrEP regimen.
Aging-induced dysbiosis worsens sepsis severity but is attenuated by probiotics in D-galactose-administered mice with cecal ligation and puncture model.
PLoS One
October 2024
Department of Microbiology, Center of Excellence on Translational Research in Inflammation and Immunology (CETRII), Chulalongkorn University, Bangkok, Thailand.
Introduction: Despite the well-established effects of aging on brain function and gut dysbiosis (an imbalance in gut microbiota), the influence of aging on sepsis-associated encephalopathy (SAE) and the role of probiotics in this context remain less understood.
Methods: C57BL/6J mice (8-week-old) were subcutaneously administered with 8 weeks of D-galactose (D-gal) or phosphate buffer solution (PBS) for aging and non-aging models, respectively, with or without 8 weeks of oral Lacticaseibacillus rhamnosus GG (LGG). Additionally, the impact of the condition media from LGG (LCM) was tested in macrophages (RAW 264.
Impact of Age and Concurrent Antiseizure Medication Use on Lacosamide Dose to Concentration Ratio and Dosing in Pediatric Patients.
J Pediatr Pharmacol Ther
October 2024
Department of Pediatrics (SJP, JWW) and Division of Neurology (JWW; ORCID 0000-0002-4735-3431), College of Medicine, The University of Tennessee Health Science Center, Memphis TN; and.
Objective: To evaluate age, adjunctive antiseizure medication (ASM), and specific ASMs on lacosamide (LCM) weight normalized dose-to-concentration ratio (DCR) and US Food and Drug Administration (FDA) dosing guidelines in pediatric patients.
Methods: Patients 1 mo to ≤18 years with a LCM serum concentration between October 2009 and June 2017 were considered. Demographics, LCM DCR, and adjunctive ASM were recorded.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!